Identification of lipid metabolism-related genes in dapagliflozin treated rats with diabetic cardiomyopathy by bioinformatics
BackgroundDiabetic cardiomyopathy (DCM) is a heart disease caused by the metabolic disorders of glucose and lipids associated with diabetes, leading to heart failure and death in diabetic patients. Dapagliflozin (DAPA) serves as a treatment for managing blood glucose levels in individuals with type...
Saved in:
| Main Authors: | Xun Huang, Yunhong Wang, Rong Wan, Zhigang You, Lin Huang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1525831/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nanocarrier-encapsulated SGLT-2 inhibitor (dapagliflozin) protects against diabetic cardiomyopathy by reducing myocardial fibrosis
by: CY Li, et al.
Published: (2025-04-01) -
Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial
by: Thomas H. Marwick, et al.
Published: (2025-05-01) -
Deciphering the role of crucial miRNAs involved in diabetic cardiomyopathy through a multiomics approach
by: Bhagyalakshmi Balakrishnan, et al.
Published: (2025-07-01) -
Discovering new hub genes of dilated cardiomyopathy
by: Jun‐Yan Zhu, et al.
Published: (2025-08-01) -
Bioinformatics analysis combined with experimental validation reveals the novel mechanisms of multi-targets of dapagliflozin attenuating diabetic liver injury
by: Pengyu Wang, et al.
Published: (2025-05-01)